03839 CT ENTERPRISE
- 0.850
- -0.030-3.41%
CT ENTERPRISE News
Chia Tai Enterprise International (03839.HK) announced first-quarter results. Profit attributable to shareholders of US$989,000 decreased by 43.39% year-on-year
Chia Tai Enterprise International (03839.HK) announced results for the first quarter of 2024, with revenue of US$54.654 million, up 25.64% year on year; profit attributable to shareholders of the company was US$989 million, a decrease of 43.39% year on year.
正大企業國際：截至二零二四年三月三十一日止三個月之未經審核業績
Zhitong Hong Kong Stock Investment Calendar | May 9
Hong Kong Stock Investment Calendar | May 9, 2024
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Chia Tai Enterprise International (03839.HK) plans to hold a board meeting on May 9 to approve the first quarter results
Gelonghui, April 24, 丨 Chia Tai Enterprise International (03839.HK) announced that it will hold a board meeting on May 9, 2024 (Thursday) to approve (among others) the unaudited results of the Company and its subsidiaries for the 3 months ended March 31, 2024.
正大企業國際：2023年年報
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Chia Tai Enterprise International (03839) announced annual results, with profit attributable to shareholders of US$2.553 million
Chia Tai Enterprise International (03839) announced results for the year ended December 31, 2023, with revenue of 174 million...
Chia Tai Enterprise International (03839.HK)'s annual revenue rose 9.3% to US$174 million
On February 23, GLONGHUI | Chia Tai Enterprise International (03839.HK) announced that for the year ended December 31, 2023, the company's revenue increased 9.3% to US$174 million. However, overall gross margin fell from 24.6% in 2022 to 19.4% in 2023, mainly due to falling prices of chlormycin products and an increase in trading business with lower profit margins. Profit attributable to shareholders of the company was US$2.6 million (2022: loss of US$6.7 million). The shift from loss to profit is mainly due to improvements in industrial business performance, which should account for Yichumingtong's profit and loss losses from 2022
正大企業國際：截至二零二三年十二月三十一日止年度之全年業績公告
Chia Tai Enterprise International (03839.HK): Zhang Manqi was appointed as an independent non-executive director
Gelonghui, Feb. 23 | Chia Tai Enterprise International (03839.HK) announced that Zhang Manqi has been appointed as an independent non-executive director and a member of the Remuneration Committee and Nomination Committee.
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Chia Tai Enterprise International (03839.HK) held a board meeting on February 23 to approve annual results
GLONGHUI Feb. 8 | Chia Tai Enterprise International (03839.HK) announced that it will hold a board meeting on February 23, 2024 (Friday) to approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider payment of a final dividend (if any).
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Chia Tai Enterprises Reports Nine-Month Profit of $2.1 Million
Chia Tai Enterprises International (HKG:3839) posted an attributable profit of $2.1 million in the January to September period, versus an attributable loss of $6.9 million a year ago. The chlortetracy
CT ENTERPRISE: Unaudited Results for the Nine Months Ended 30 September 2023
Intraday quick overview | The three major indices rushed higher and fell, and the index rose slightly; pharmaceutical stocks and domestic housing stocks had the highest gains, Pharmaceuticals Biotech rose more than 5%, and Country Garden rose more than 4%
Most of the Internet of Technology stocks rose, Kuaishou and Tencent rose nearly 2%; most auto stocks fell; Xiaopeng Motor fell by more than 4%, and Zero Sports fell by more than 3%.
Can we expect a large-scale market? Pharmaceutical funds have rebounded across the board. What I'm most concerned about is actually...
What pharmaceutical fund managers are most worried about now is whether non-pharmaceutical funds and top players will think about it again in the midst of a ferocious pharmaceutical backlash.
Analysis
Price Target
No Data
